Literature DB >> 5445046

The effect of isoproterenol on airway obstruction in cystic fibrosis.

E A Featherby, T R Weng, H Levison.   

Abstract

The effect of isoproterenol inhalations was studied on 95 occasions in 47 patients with cystic fibrosis.Spirometric and airway resistance measurements showed small but statistically significant changes in the MMEF, MBC and airway resistance, although there was considerable variation from patient to patient. Over-inflation of the lungs, as indicated by a high thoracic gas volume, was not significantly decreased by the administration of the drug.It is suggested that before using isoproterenol routinely as a treatment for cystic fibrosis, response to this drug should be measured in each individual patient.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 5445046      PMCID: PMC1946679     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  10 in total

1.  A THERAPEUTIC REGIMEN FOR PATIENTS WITH CYSTIC FIBROSIS.

Authors:  L W MATTHEWS; C F DOERSHUK; M WISE; G EDDY; H NUDELMAN; S SPECTOR
Journal:  J Pediatr       Date:  1964-10       Impact factor: 4.406

2.  The effect of a bronchodilator aerosol on ventilatory capacity in fibrocystic disease of the pancreas.

Authors:  B GANDEVIA; C ANDERSON
Journal:  Arch Dis Child       Date:  1959-12       Impact factor: 3.791

3.  Pulmonary function in cystic fibrosis of the pancreas.

Authors:  J R WEST; S M LEVIN; P A DI SANT'AGNESE
Journal:  Pediatrics       Date:  1954-02       Impact factor: 7.124

4.  Airways obstruction before and after isoprenaline, histamine, and presnisolone in patients with chronic obstructive bronchitis.

Authors:  E A Oppenheimer; M Rigatto; C M Fletcher
Journal:  Lancet       Date:  1968-03-16       Impact factor: 79.321

5.  Obstructive disease of the airways in cystic fibrosis.

Authors:  R B Mellins; O R Levin; R H Ingram; A P Fishman
Journal:  Pediatrics       Date:  1968-03       Impact factor: 7.124

6.  Standards of pulmonary function in children.

Authors:  T R Weng; H Levison
Journal:  Am Rev Respir Dis       Date:  1969-06

7.  Measurement of response to isoprenaline in asthmatic children.

Authors:  E A Featherby; T R Weng; H Levison
Journal:  Arch Dis Child       Date:  1969-06       Impact factor: 3.791

8.  Relationship of mechanics of ventilation to lung volumes in children and young adults.

Authors:  M Kamel; T R Weng; E A Featherby; W S Jackman; H Levison
Journal:  Scand J Respir Dis       Date:  1969

9.  Pulmonary pathophysiology in cystic fibrosis.

Authors:  F R Beier; A D Renzetti; M Mitchell; S Watanabe
Journal:  Am Rev Respir Dis       Date:  1966-09

10.  A new method for measuring airway resistance in man using a body plethysmograph: values in normal subjects and in patients with respiratory disease.

Authors:  A B DUBOIS; S Y BOTELHO; J H COMROE
Journal:  J Clin Invest       Date:  1956-03       Impact factor: 14.808

  10 in total
  4 in total

1.  Association of cystic fibrosis with allergy.

Authors:  J O Warner; B W Taylor; A P Norman; J F Soothill
Journal:  Arch Dis Child       Date:  1976-07       Impact factor: 3.791

2.  Cystic fibrosis, atopy, and airways lability.

Authors:  M Silverman; F D Hobbs; I R Gordon; F Carswell
Journal:  Arch Dis Child       Date:  1978-11       Impact factor: 3.791

3.  Response to aerosol salbutamol, SCH 1000, and placebo in cystic fibrosis.

Authors:  M Kattan; A Mansell; H Levison; M Corey; I R Krastins
Journal:  Thorax       Date:  1980-07       Impact factor: 9.139

4.  Impaired cardiac and peripheral hemodynamic responses to inhaled β₂-agonist in cystic fibrosis.

Authors:  Erik H Van Iterson; Stephen R Karpen; Sarah E Baker; Courtney M Wheatley; Wayne J Morgan; Eric M Snyder
Journal:  Respir Res       Date:  2015-09-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.